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In	chronic	experiments	on	five	groups	of	WAG/Rij	rats	(a	genetic	model	of	absence	epilepsy;	
six	animals	 in	each	group),	we	 recorded	EEG	activity	 from	 the	S1po	cortical	 area	 through	
implanted	electrodes	and	subjected	 the	cortex	 to	 the	action	of	 four	agents	affecting	L-	and	
T-type	calcium	channels	(injections	through	an	implanted	cannula).	A	blocker	of	L-type	chan-
nels,	 verapamil	 hydrochloride,	 an	 agonist	 of	 these	 channels,	 Bay	K8644,	 an	 antagonist	 of	
T-type	calcium	channels,	L-ascorbate,	and	an	agonist	of	the	latter	channels,	PMA,	were	used.	
The	parameters	of	7-	to	10-Hz	spike-wave	discharges,	SWDs,	spontaneously	generated	in	the	
cortex	of	this	rat	strain	(frequency	of	SWDs,	mean	duration	of	the	latter,	and	their	number)	
were	measured	within	 the	baseline	 interval	 (before	 injections)	and	within	 three	subsequent	
20-min-long	post-injection	intervals.	Normal	saline	was	injected	in	the	control	group.	There	
were	no	significant	differences	in	the	mean	peak	frequency	in	SWDs	between	all	examined	
groups	 (P	 >	 0.05	 in	 all	 cases).	Verapamil	 significantly	 (by	more	 than	 40%;	P	 <	 0.05)	 de-
creased	the	mean	SWD	duration	throughout	 the	entire	period	of	post-injection	observation.	
The	dynamics	of	the	Bay	K8644	effects	were	rather	similar,	but	the	intensity	of	SWD	dura-
tion	 changes	was	 somewhat	 smaller.	Both	 the	 above	agents	 in	 the	doses	used	dramatically	
decreased	 the	 number	 (frequency	 of	 appearance)	 of	 SWDs	within	 the	 observation	 period.	
L-ascorbate	 also	 suppressed	SWD	generation.	The	duration	of	 these	phenomena	decreased	
mildly,	while	 their	number	dropped	dramatically.	 In	 the	PMA	group,	 the	number	of	SWDs	
increased	significantly	(by	50%,	P <	0.05)	within	the	first	20-min-long	interval,	but	this	was	
not	observed	within	subsequent	intervals.	These	findings	confirm	that	blocking	or	activating	
of	L-	and	T-type	Ca2+	channels	in	the	S1po	area	(cortical	focus	area)	can	significantly	control	
generation	of	SWDs	during	absence	seizures.	Possible	mechanisms	underlying	actions	of	the	
tested	agents	are	discussed.
Keywords: absence seizures, spike-wave discharges, WAG/Rij rats, L- and T-type 
calcium channels.
1	 Neurosciences	 Research	 Center,	 Tabriz	 University	 of	 Medical	 Sciences,	
Tabriz,	Iran.
2	 Drug	 Applied	 Research	 Center,	 Tabriz	 University	 of	 Medical	 Sciences,	
Tabriz,	Iran.
3	 Institute	 Für	 Physiologie	 I,	 Westfӓlische	 Wilhelms-Universitӓt,	 Münster,	
Germany,	and	Shefa	Neuroscience	Research	Center,	Tehran,	Iran.
4	 Urmia	 Neurophysiology	 Research	 Ceter,	 Urmia	 University	 of	 Medical	
Sciences,	Urmia,	Iran.
Correspondence	should	be	addressed	to	P.	Shahabi	
(e-mail:	parvizshahabi@gmail.com).
INTRODUCTION
Absence	 seizures	 are	 believed	 to	 be	 a	 phenomenon	
typical	 of	 generalized	 non-convulsive	 epilepsies.	
These	 events	 are	 characterized	 by	 some	 general	
features,	like	brief	unresponsiveness	to	environmental	
stimuli	 and	 interruption	 of	 consciousness.	 Absence	
seizures	 are	 characterized	 by	 symmetric,	 bilateral,	
and	synchronous	3-Hz	spike-wave	discharges	(SWDs)	
[1].	 In	 absence	 epilepsy,	 abnormal	 motor	 activities	
may	not	be	recognized	[2].	The	annual	incidence	rate	
of	 absence	 epilepsy	 has	 been	 estimated	 to	 be	 about	 
1.2-7.1	per	100,000	in	different	populations	[3].
Wistar	Albino	Glaxo	Rijswijk	 (WAG\Rij)	 rats	 are	
described	to	be	a	genetic	model	for	absence	epilepsy;	
these	animals	exhibit	7-	to	10-Hz	SWDs	lasting	from	
1	 to	 30	 sec	 [4,	 5].	 SWDs	 are	 not	 generated	 during	
active	wakefulness	and	REM	sleep,	but	they	occur	in	
wakefulness	with	a	low	level	of	alertness	[6].	Sixteen	
to	twenty	discharges	per	hour	are	usually	recorded	[7].	
During	seizures,	WAG/Rij	 rats	 remain	 immobile	and	
twitch	 their	vibrissae	 and	 facial	muscles	 [8].	 In	 line	
with	 cortical	 focus	 theory	 and	nonlinear	 association	
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analysis	 of	 SWDs,	 the	 S1po	 is	 the	 initiation	 site	
for	 SWDs.	 Seizure	 activities	 that	 were	 produced	 in	
this	 zone	disseminated	 quickly	 in	 other	 areas	 of	 the	
cortex	 and	 thalamus.	 It	 was	 found	 that	 injection	 of	
ethosuximide	 into	 the	ventrobasal	 thalamus	and	RTN	
demonstrated	a	 low	efficacy	 in	suppression	of	SWDs	
[9,	10].	
There	 is	 strong	 evidence	 that	 entry	 of	 Ca2+	 ions	
into	 neurons	 plays	 a	 significant	 role	 in	 generation	
of	 seizures	 [11].	 Throughout	 epileptiform	 activity,	
intracellular	 Ca2+	 concentration	 increases,	 while	
extracellular	Ca2+	concentration	is	reduced	[12].	High-	
and	 low-voltage-activated	 (HVA	 and	 LVA)	 calcium	
channels	 are	 involved	 in	 the	 regulation	 of	 neuronal	
excitability	and	production	of	absence	SWDs.	High-
voltage-activated	calcium	channels	 include	different	
subunits	 (α,	 β,
,
γ,	 and	 σ).	 In	 mammals,	 genome	
expression	 forms	 three	 large	 families	of	 subtype	β1.	
Four	different	kinds	of	L-type	HVA	calcium	channels	
belong	 to	 the	 Cav1	 family	 (Cav1	 through	 Cav1.4)	
[13]. Cav1.2	 and	 Cav1.3	 channels	 are	 located	 on	
neuronal	 membranes,	 generally	 on	 the	 dendrites	
[14].	 In	 hippocampal	 neurons,	 calcium	 currents	
in	 cells	 depend	 mostly	 on	 the	 presence	 of	 L-type	 
channels	[15].	
Low-voltage-act ivated 	 T-type	 channels 	 are	
monomers	of	β
1
	 subunit,	 and	 their	 activation	 results	
from	relatively	small	membrane	depolarization.	Such	
channels	are	members	of	the	Ca
v
3	family,	and	they	are	
divided	into	three	groups	(Ca
v
3.1-Ca
v
3.3)	[13].	T-type	
calcium	channels	play	key	 roles	 in	 the	 regulation	of	
neuronal	excitability.	Hyperactivity	of	these	channels	
causes	 some	neurological	disorders,	 such	as	absence	
seizures	and	neuropathic	pains	[16].	It	was	mentioned	
that	 the	activity	of	T-type	channels	 is	 increased	 in	a	
mouse	model	of	epilepsy	[17].	
In	 our	 study,	 we	 examined	 the	 role	 of	 L-	 and	
T-type	calcium	channels	on	SWDs	recorded	from	the	
cortical	S1po	area	 in	WAG/Rij	 rats.	The	 experiment	
addressed	 an	 important	 question	 of	 how	 SWDs	 can	
be	changed	after	 injections	of	agents	 that	effectively	
influence	 the	 above-mentioned	 channels.	 These	 are	
a	 blocker	 of	 L-type	 calcium	 channels,	 verapamil	
hydrochloride;	an	L-type	channel	agonist,	Bay	K8644	
(methyl-1 ,4-dihydro-2,6-dimethyl-3-ni t ro-4-(2-
trifluoromethylphenyl)-pyridine-5-carboxylate),	 an	
antagonist	 of	T-type	 calcium	 channels,	 L-ascorbate;	
and	 T-type	 channel 	 agonis t , 	 PMA	 (phorbol	
12-myristate	13-acetate,	a	protein	kinase	C	activator).	
METHODS
Animals and Drugs. Experiments	were	carried	out	on	
30	WAG/Rij	rats	(age	from	4	to	6	months,	body	mass	
from	 220	 to	 260	 g).	Animals	were	maintained	 under	
standard	lab	conditions	(22	°C,	light/dark	cycle	12/12	h,	 
and	 unlimited	 access	 to	 food	 and	 water	 until	 the	
presupposed	time	of	experiment).	
Bay	K8644,	 verapamil,	 and	PMA	were	 purchased	
from	Tocris	(Great	Britain),	L-ascorbate	was	purchased	
from	Sigma	 (USA).	Verapamil	and	L-ascorbate	were	
dissolved	 in	 0.9%	 saline.	 For	 injections	 	 into	 the	
S1po	cortex	(in	 the	volume	of	1	µl),	Bay	K8644	was	
dissolved	in	0.9%	saline	and	ethanol.	To	inject	500	nM	 
PMA,	 a	 stock	 solution	 containing	 2	 mM	 PMA	 in	
DMSO	 was	 dissolved	 in	 saline	 to	 the	 necessary	
concentration.
Surgical Procedure. Rats	 were	 anesthetized	 i.p.	
by	ketamine	(80	mg/kg)	and	xylazine	(5	mg/kg)	[18].	
All	animals	were	implanted	with	two	cortical	stainless	
steel	electrodes	 for	EEG	recording	and	a	cannula	 for	
drug	injection.	The	coordinates	of	the	cannula	tip	were	
the	following:	2.1	mm	posterior,	5.5	mm	lateral	to	the	
bregma,	 and	 4.0	mm	vertical	 from	 the	 skull	 surface	
(according	to	the	stereotaxic	atlas	[19]).
The	 monopolar	 EEG	 recording	 electrode	 was	 in	
the	 frontal	 cortical	 region	 of	 the	 right	 hemisphere	
(coordinates:	AP	=	0.22,	L	=	0.24,	and	V	=	0.26),	while	
the	 reference	 electrode	 was	 in	 the	 occipital	 cortex.	
Electrodes	 were	 fixed	 in	 the	 sockets	 by	 pins.	 The	
cannula	socket	was	fixed	to	the	skull	by	dental	cement.
Recording and Injection. After	 1-week	 recovery	
from	 surgery,	 rats	 were	 settled	 in	 a	 Faraday	 cage,	
and	EEG	was	 recorded	 from	 freely	moving	 animals.	
Spike-wave	discharges	 (Fig.	1)	were	recorded	20	min	
before	 and	 three	 times	within	 20-min-long	 intervals	
after	 drug	 injections.	Mild	 natural	 stimuli	 (moderate	
sound	 or	 touch)	 were	 applied	 to	 prevent	 the	 animal	
from	 sleeping.	 Separate	 groups	 of	 rats	were	 used	 to	
characterize	 the	 effects	 of	 verapamil,	 Bay	 K8644,	
L-ascorbate,	and	PMA.	For	bilateral	injection	of	1	µl	of	
the	solution,	a	27	G	cannula	needle	in	the	guide	cannula	
was	connected	to	a	10	µl	Hamilton	syringe.	A	dose	of	
22.4	µmol	of	Bay	K8644	was	injected.	The	verapamil	
hydrochloride	injection	dose	was	40	µmol.	In	addition,	
500	nmol	of	PMA	and	100	µmol	of	L-ascorbate	were	
injected	in	the	respective	animal	groups.
Statistical Analysis.  For	 statistical	 analyses,	
SPSS13	 software	was	used.	Variables	 (mean	within-
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the	baseline	values	taken	as	100%.	During	the	baseline	
period,	EEG	was	recorded	for	20	min,	and	the	rats	did	
not	receive	any	drugs	or	saline.	
Effects of Verapamil and Bay K8644 on SWDs. 
The	 SWD	 parameters	 during	 the	 above-mentioned	
20-min-long	periods	 for	Bay	K8644,	verapamil,	 and	
control	groups	(six	rats	in	each	group)	were	compared	
using	one-way	ANOVA.	No	significant	dissimilarities	
in	 the	 mean	 whithin-SWD	 peak	 frequency	 between	
experimental	groups	were	found	(P	<	0.05).	
In	the	control	group,	the	mean	SWDs	within	the	first	
20-min-long	post-injection	interval	practically	did	not	
differ	from	the	baseline	value.	Later	on,	a	mild	 trend	
toward	a	decrease	in	this	index	was	observed	(Figs.	2A	
and	3A).	At	the	same	time,	an	analogous	trend	toward	
a	decrease	in	the	values	of	the	mean	number	of	SWDs	
was	quite	obvious	throughout	the	entire	post-injection	
observation	 period	 in	 the	 control	 (saline)	 group	 
(Figs.	2B	and	3B)	
Comparison	 of	 the	 groups	 revealed	 remarkable	
effects	 of	 the	 agents	 on	 the	 number	 and	 duration	 of	
SWDs	 (P <	 0.05).	 During	 the	 first	 20-min	 interval	
following	 injection	of	Bay	K8644	and	verapamil,	 the	
mean	duration	of	SWDs	in	the	Bay	K8644	group	was	
smaller	than	that	in	the	control	group	(71	±	13.5%	vs 
102	±	14.6%).	In	the	verapamil	group	compared	to	the	
control	group,	an	even	greater	(56	±	12.8	%	vs 102	±	 
±	14.6%)	 reduction	of	mean	duration	 in	 the	 first	20-
min	phase	was	found.	
The	diference	between	the	mean	duration	of	SWDs	
in	verapamil	hydrochloride	and	control	groups	during	
the	second	and	third	20	min	was	significant	(P	<0.05).	
Within	 the	 second	20-min	phase,	 the	decrease	 in	 the	
SWD	 duration	 in	 the	 verapamil	 group	 was	 smaller	
compared	to	the	control	(50.0	±	7.3	and	86.0	±	6.5%,	
F i g. 1.	 Typical	 spike-wave	 discharge	 recorded	 from	 the	 S1po	
cortex	of	a	WAG/	Rij	rat.
Р и с. 1.	Типовий	розряд	пік-хвиля,	відведений	від	кортикальної	
зони	S1po	щура	WAG/	Rij.
F i g. 2.	 Dynamics	 of	 the	 normalized	
effects	 (%)	 of	 verapamil	 hydrochloride	
(40	 µmol,	 2)	 and	 Bay	K8644	 (22.4	 µmol,	
3)	 on	 the	 duration	 (A)	 and	 number	 (B)	
of	 spike-wave	 discharges	 within	 three	
subsequent	 20-min-long	 post-injection	
intervals.	 1)	 Control.	 Baseline	 indices	 are	
taken	 as	 100%.	 Asterisks	 show	 cases	 of	
significant	 (P	 <	 0.05)	 differences	 from	 the	 
baseline	values.	
Р и с. 2.	 Динаміка	 нормованих	 величин	
ефектів	 верапамілу	 гідрохлориду	
(40	мкмоль)		та	Bay	K8644	(22.4	мкмоль)	
щодо	 тривалості	 (А)	 та	 кількості	 (B)	
розрядів	 пік-хвиля	 в	 межах	 трьох	
послідовних	 20-хвилинних	 інтервалів	
після	ін’єкцій.
SWD	peak	 frequency,	mean	duration,	and	number	of	
SWDs)	were	analyzed	by	intragroup	repeated	measures	
and	 one-way	 ANOVA	 between	 groups.	 The	 Sidok	
test	 was	 applied	 for	 post-hoc	 analysis.	Values	were	
expressed	as	a	percentage	with	respect	to	baselines.	P 
values	smaller	than	0.05	were	considered	statistically	
significant.	The	baseline	was	calculated	as	100%.
Histological Verification. After	 euthanizing	 the	
animals by	 a	 high	 dose	 of	 ketamine,	 we	 quickly	
removed	 the	brains	and	 fixed	 them	 in	10%	formalin.	
The	 locations	 of	 the	 cannula	 tips	 were	 verified	 by	
cresyl	violet	staining	in	coronal	sections	of	the	brain.
RESULTS
To	 evaluate	 the	 effects	 of	 Bay	 K8644,	 verapamil,	
L-ascorbate,	 PMA,	 and	 control	 (saline)	 injections	 on	
SWDs,	the	mean	peak	frequency	in	these	events,	their	
mean	 duration,	 and	 number	 measured	 within	 three	
20-min-long	intervals	after	injection	of	the	drugs	were	
analyzed.	The	saline	group	served	as	the	control.	The	
data	 were	 averaged	 and	 presented	 as	 percentages	 of	
100 µV
5 sec
0
20
40
60
80
100
120
140
Basline 20 40 60
0
20
40
60
80
100
120
Basline 20 40 60
%
min min
A B
%
NEUROPHYSIOLOGY	/	НЕЙРОФИЗИОЛОГИЯ.—2013.—T.	45,	№	4354
M.	SADIGHI,	P.	SHAHABI,	A.	GORJI,	et	al.
respectively).	During	 the	 third	20-min	 interval,	 there	
was	also	a	decrease	in	the	mean	duration	in	comparison	
with	 the	 control	 group	 (55	 ±	 7.1	 and	 89	 ±	 12.6%;	 
Fig.	2A).
Injections	 of	 Bay	 K8644	 also	 led	 to	 significant	
decreases	 in	 the	 mean	 duration	 of	 SWDs	 during	
the	 entire	 60-min-long	 period	 of	 post-injection	
observation.	The	 dynamics	 of	 changes	 in	 this	 index	
were	rather	similar	 to	 that	 in	verapamil-injected	rats,	
but	 the	 relative	 intensity	of	 the	drops	was	somewhat	
smaller	(Fig.	2A).
In	 verapamil-injected	 animals,	 the	mean	 numbers	
of	 SWDs	were	 also	 dramatically	 smaller	 than	 those	
observed	in	control	animals.	The	respective	figures	in	
the	 first	20	min	were	27	±	8.51%	vs	 90	±	19.9%,	 in	
the	 second	 20-min	 interval	 they	were	 14	 ±	 5.9%	 vs 
78	 ±	 6.1%,	 and	 in	 the	 third	 period	 they	 were	 
12	±	8.7%	and	61	±	6.7%	(Fig.	2B).
During	 the	 first,	 second,	and	 third	20-min	phases,	
considerable	differences	in	the	number	of	SWDs	were	
also	noted	between	the	Bay	K8644	and	control	groups.	
These	were	21	±	11.0	vs	90	±	19.9%,	8.0	±	5.1	vs	78	±	 
±	 6.1%,	 and	 5.0	 ±	 5.1	 vs	 61	 ±	 7.0%	 ,	 respectively	 
(Fig.	2B).
The	results	of	three	experimental	groups	compared	
using	 the	 repeated	measures	 test	 showed	 that,	during	
the	 first,	 second	 and	 third	 20-min-long	 intervals	
after	 injection,	 there	were	no	 significant	differences	
between	 the	values	 of	 the	mean	peak	 frequency	 and	
mean	duration	of	SWDs	at	these	time	points	(P >	0.05	
in	all	cases).	
Effects of L-Ascorbate and PMA on SWDs. 
Statistical	analyses	showed	that	the	mean	within	SWD	
peak	 frequency	 did	 not	 change	 significantly	 in	 the	
L-ascorbate	and	PMA	groups	 in	comparison	with	 the	
control	group	(P >	0.05).	During	the	first	20	min	post-
injection,	there	was	a	noticeable	decrease	in	the	mean	
duration	of	SWDs	in	the	L-ascorbate	group	and	a	mild	
trend	toward	increase	in	this	index	in	the	PMA	group;	
the	 difference	 between	 these	 groups	was	 significant	
(75	 ±	 21.0	 vs	 109	 ±	 3.6%).	Within	 the	 second	 and	
third	20-min-long	intervals	after	 injections,	 the	mean	
durations	did	not	show	significant	differences	between	
the	three	groups	(P >	0.05;	Fig.	3A).
The	mean	number	of	SWDs	during	the	first	20	min	 
in	 the	 PMA	 group	 was	 significantly	 greater	 (150	 ±	
±	17.7%)	compared	 to	 the	control	 (90	±	19.9%)	and	
baseline	values.	
Within	 the	 subsequent	 period	 (second	 and	 third	
intervals	of	observation),	 the	mean	number	of	SWDs	
in	the	PMA	group	decreased	below	the	baseline	value	
(Fig.	3B).
Injections	of	L-ascorbate	led	to	dramatic	decreases	
in	the	mean	number	of	SWDs	within	the	entire	period	
of	 60-min-long	 post-injection	 observation.	 Within	
the	first,	second,	and	third	20-min-long	intervals,	 the	
respective	 values	 were	 20	 ±	 9.2%,	 15	 ±	 7.4%,	 and	 
10	±	8.5%,	as	compared	to	the	baseline	value;	all	these	
figures	were	significantly	smaller	(P	<	0.05)	than	the	
respective	values	in	the	control	group	(Fig.	3B).	
All	three	consequent	values	of	the	normalized	mean	
number	 of	 SWDs	 in	 the	 L-ascorbate	 group	 differed	
significantly	(P <	0.05)	from	the	corresponding	values	
in	the	PMA	group.	
DISCUSSION
Calcium	 ions	 are	 significantly	 involved	 in	 the	
induction	 of	 SWDs	 in	 epilepsy.	 Extracellular	 Ca2+ 
enters	 via	 voltage-dependent	 calcium	 channels,	 like	
L-	and	T-type	channels,	across	 the	plasma	membrane	
F i g. 3.	 Dynamics	 of	 the	 normalized	 ef-
fects	of	L-ascorbate	(100	µmol,	2)	and	PMA	 
(500	nmol,	3)	on	 the	duration	(A)	and	num-
ber	 (B)	of	 spike-wave	discharges	within	 the	
post-injection	period.	Other	designations	are	
similar	to	those	in	Fig.	2.	
Р и с. 3.	 Динаміка	 нормованих	 величин	
ефектів	L-аскорбату	(100	мкмоль)	та	РМА	
(500	нмоль)	щодо	 тривалості	 (А)	 та	 кіль-
кості	 (B)	РПХ	у	межах	періоду	спостере-
ження	після	ін’єкцій.
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and	increases	the	Ca2+	concentration	in	excitable	cells	
[20].	Our	study	was	aimed	at	elucidating	the	role	of	the	
above	calcium	channels	in	the	regulation	of	SWDs	in	
WAG/Rij	rats	with	absence	seizures.	For	this	purpose,	
verapamil,	 Bay	 K8644,	 L-ascorbate,	 and	 PMA	 were	
used.	Our	observations	after	microinjections	of	 these	
drugs	into	the	rat	cortex	showed	that	both	Bay	K8644	
and	verapamil	reduced	the	mean	duration	and	number	
of	 SWDs	 considerably.	 Injection	 of	 L-ascorbate	
decreased	 the	 number	 of	 SWDs,	 while	 increases	 in	
the	mean	 duration	 and	 (especially)	 in	 the	 number	 of	
SWDs	after	 receiving	of	PMA	were	 found	within	 the	
initial	phase	of	observation.
In	 contrast	 to	 our	 results,	 a	 study	 on	 mice	
reported	 that	 when	 Bay	 K8644	 was	 injected	
intracerebroventricularly	 (i.c.v),	 this	agent	produced	
seizure	 activity	 [21].	 Furthermore,	 Bay	 K8644	
increased	 calcium	effects	 in	 an	 in vitro	 study	on	 rat	
caudate	 neurons	 [22].	 It	 was	 mentioned	 that,	 when	
introduced	in	the	nucl. accumbens	and	bed nucl.	stria 
terminalis,	Bay	K8644	exerted	an	activating	effect	on	
Cav1.3	[23].	
Although	 Bay	 K8644	 is	 an	 L-type	 Ca2+	 channel	
opener	and	pro-convulsing	drug,	it	does	not	have	such	
an	effect	in	all	models	[24].	Throughout	the	convulsion	
threshold	test	on	mice,	Bay	K8644	did	not	demonstrate	
the	 above	 action.	 In	 genetically	 epilepsy-prone	 rats	
(GEPR)	 and	 DBAr2	 mice,	 this	 drug	 could	 not	 cut	
down	audiogenic	seizures	[25,	26].	At	the	same	time,	
Bay	K8644	suppressed	SWDs	when	administrated	in	a	
certain	dose.	In	WAG/Rij	rats,	i.c.v.	injections	of	high	
concentrations	 of	 Bay	K8644	 initiated	 convulsions,	
but	administration	of	 lower	doses	did	not	cause	such	
an	effect.	As	was	reported	earlier,	administration	of	an	
L-type	Ca2+	channel	 agonist,	Bay	K8644,	 suppresses	
SWDs,	 but	 dihydropyridines	 (L-type	 Ca2+	 channel	
blockers)	 increase	SWD	incidence	 [27].	Experiments	
on	rats	[28]	demonstrated	that	Bay	K8644	suppresses	
SWDs,	 but	 administration	 of	 nimidipine	 (an	 L-type	
calcium	 channel	 antagonist)	 exerted	 a	 facilitating	
effect.	 The	 effect	 of	 Bay	 K8644	 on	 SWDs	 in	 the	
cited	 report	was	also	 found	 in	our	 study;	 thus,	 these	
data	 suggest	 that	 seizure	 activity	 can	be	 reduced	by	
the	L-type	Ca2+	channel	activator	Bay	K8644.	As	was	
determined	 by	 experiments	 with	 administration	 of	 
β
2
-adrenergic	agonists	and	GABA	agonists,	Bay	K8644	
exerts	a	dual	action	in	epilepsy.	In	convulsive	epilepsy,	
its	 action	 is	 pro-convulsing,	 but	 it	 demonstrates	 an	
antiepileptic	activity	 in	nonconvulsive	epilepsy.	The	
dual	effect	of	Bay	K8644	indicates	that	the	respective	
mechanisms	in	convulsive	and	nonconvulsive	epilepsy	
are	different	[28].	
Verapamil	 is	used	 in	 the	 treatment	of	hypertension	
(action	 on	 vascular	 smooth	 muscles)	 and	 epilepsy	
because	 it	 can	 block	 L-type	 Ca2+	 currents	 in	 most	
cell	 types	 [29].	 As	 was	 reported,	 this	 calcium	
channel	 blocker	 decreased	 the	 seizure	 frequency	
in	 a	 patient	 that	 suffered	 from	 refractory	 partial	
epilepsy	 [30].	 In	patients	with	 the	status epilepticus 
after	 i.v.	 administration	of	verapamil,	 consciousness	
was	 regained;	 according	 to	 EEG,	 no	 electrical	
manifestations	 of	 the	 above	 status	 were	 recognized	
[31].	 Verapamil	 reduced	 the	 rate	 and	 duration	
of	 burst	 discharges	 in	 CA3 	 pyramidal	 cells	 in	
hippocampal	 slices	 [32].	 In	 investigations	 on	 slices	
of	 the	hippocampus	and	frontal	neocortex,	verapamil	
blocked	epileptiform	field	potentials	and	paroxysmal	
depolarization	shifts	[33].
Verapamil	 reduces	 the	Ca2+	level	 in	 the	 cytoplasm	
and	 induces	 repolarization	 in	 cells	 by	 preventing	
Ca2+	 entry	 through	 calcium	 channels,	 influencing	
transmembrane	 Na+/Ca2+	 exchange,	 and	 activating	
potassium	channels	sensitive	to	intracellular	Ca2+[34].	
Redox	 agents,	 such	 as	 L-ascorbate,	 can	 change	
gating	of	T-type	Ca2+	channels.	Ca
v
3.2	can	be	inhibited	
by	ascorbate,	but	this	agent	does	not	have	any	effect	on	
Ca
v
3.1	and	Ca
v
3.3	T-type	channels.	Regulation	of	 the	
neuronal	excitability	depends	on	Ca
v
3.2	channels;	so,	
ascorbate	as	a	neuromodulator	of	these	channels	can	be	
involved	 in	modulation	of	neuronal	 firing.	Ascorbate	
modulates	T-currents	and	low-threshold	spikes	in	nRT	
neurons	 [35,	 36].	 In	 both	 extra-	 and	 intra-cellular	
brain	spaces,	ascorbate	provides	dynamic	changes	 in	
physiological	and	pathophysiological	situations	[37].
The	 molecular	 mechanism	 that	 explains	 the	
inhibitory	effect	of	L-ascorbate	on	Ca
v
3.2	channels	is	
based	 on	metal-catalyzed	 oxidation	 (MCO).	During	
this	process,	reactive	oxygen	species	(ROSs)	produced	
by	ascorbate	oxidize	 a	histidine	 residue	 in	domain	 I	
S3-S4	 region	 of	 the	 channels.	 Following	 oxidation	
of	the	C2	position	of	the	histidine	imidazole	ring	and	
formation	 of	 2-oxo-histidine,	 calcium	 channels	 are	
blocked,	 and	 the	 Ca2+	 intracellular	 concentration	 is	
reduced	[38,35].	
Neurotransmitter	 and	 hormones	 can	 regulate	
T-channel 	 ac t iv i ty 	 through	 some	 s igna l ing	
intermediates,	 like	 protein	 kinases	 A	 (PKA)	 and	
C	 (PKC)	 [39].	 In	 an	 earlier	 study	 on	 rat	 dorsal	 root	
ganglion	(DRG)	neurons,	it	was	shown	that	T-currents	
were	 inhibited	 after	 application	 of	 10	 nm	 PMA	 (an	
activator	of	PKC).	 In	Purkinje	cells	 from	 the	canine	
heart	and	 in	 the	clonal	GHs	 line	of	anterior	pituitary	
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cells,	 PKC	 activators	 inhibited	 T-currents	 [40,	 41].	
In	 parallel	 to	 our	 study,	 it	 is	 discovered	 that	Ca
v
3.2	
channel	 activities	 were	 increased	 by	 PMA	 in	 the	
Xenopus	 oocyte	 system.	 PMA	 activates	 PKC	 via	
phosphorylation	 of	 β1	 subunits	 in	 II-III	 loops	 of	
voltage-dependent	 calcium	 channels;	 this	 event	
activates	 these	channels	and	 increases	calcium	entry	
into	neurons	[42].	
In	conclusion,	the	data	obtained	in	our	study	suggest	
that	 both	 BAY	K8644	 and	 verapamil	 hydrochloride	
reduce	 the	 incidence	 of	 SWDs	 in	 EEG	 of	WAG/Rij	
rats	 by	 affecting	 the	 functioning	 of	 L-type	 calcium	
channels. 	 L-Ascorbate	 blocks	 Ca
v
3.2	 channels	
and	 reduces	 the	 number	 of	 SWDs.	 PMA	 provides	
phosphorylation	 of	 Ca
v
3.2	 channels	 and	 increases	
seizure	 activity.	 Thus,	 both	 L-	 and	T-	 type	 calcium	
channels	 play	 considerable	 roles	 in	 regulating	 of	
SWDs	in	absence	seizures.	
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РОЛЬ	КАЛЬЦІЄВИХ	КАНАЛІВ	L-	ТА	T-ТИПІВ	У	
РЕГУЛЯЦІЇ	АБСАНСНИХ	СУДОМ	У	ЩУРІВ	ЛІНІЇ	  
WAG/	Rij
1	Дослідницький	центр	нейронаук	Тебризького	медичного	
університету	(Іран).	  
2	Центр	прикладних	досліджень	фармакологічних	агентів	
Тебризького	медичного	університету	(Іран). 
3	Перший	Інститут	фізіології	Вестфальського	Університе-
ту	Вільгельма,	Мюнстер	(ФРН)	та	Дослідницький	Центр	
нейро	наук	Шефа,	Тегеран	(Іран). 
4	Дослідницький	центр	з	нейрофізіології	Медичного	уні-
верситету	Урмії	(Іран).
Р	е	з	ю	м	е
У	 хронічних	 експериментах	 на	 п’яти	 групах	 щурів	 лінії	
WAG/Rij	 (генетична	 модель	 абсанс-епілепсії;	 шість	 тва-
рин	у	кожній	групі)	ми	відводили	ЕЕГ-активність	від	кор-
тикальної	зони	S1po	через	імплантовані	електроди	і	підда-
вали	кору	дії	чотирьох	агентів,	що	впливають	на	кальцієві	
канали	L-	та	T-типів	(ін’єкції	через	імплантовану	канюлю).	
Використовували	блокатор	кальцієвих	каналів	L-типу	вера-
памілу	гідрохлорид,	агоніст	цих	каналів	Bay	K8644,	антаго-
ніст	кальцієвих	каналів	T-типу	L-аскорбат	та	агоніст	остан-
ніх	каналів	PMA.	Вимірювали	параметри	розрядів	пік-хвиля	
(РПХ,	частота	7–10	Гц),	котрі	спонтанно	генеруються	у	корі	
головного	мозку	щурів	указаної	лінії	(частоту	в	межах	РПХ,	
середню	тривалість	останніх	та	 їх	кількість)	протягом	 ін-
тервалу	порівняння	(перед	ін’єкціями)	та	трьох	послідовних	
20-хвилинних	 інтервалів	після	 ін’єкцій.	Щурам	контроль-
ної	групи	ін’єкували	фізіологічний	розчин.	Істотних	різниць	
між	величинами	частоти	в	межах	РПХ	у	всіх	досліджених	
групах	 не	 спостерігалося	 (P	 >	 0.05	 у	 всіх	 випадках).	 Ве-
рапаміл	 істотно	 (більш	ніж	на	40	%;	P	<	0.05)	 зменшував	
середню	тривалість	РПХ	протягом	усього	періоду	спосте-
реження	після	 ін’єкцій.	Динаміка	ефектів	Bay	K8644	була	
вельми	подібною,	але	інтенсивність	скорочення	тривалості	
РПХ	–	дещо	меншою.	Обидва	вказані	агенти	у	використаних	
дозах	зумовлювали	драматичне	зменшення	кількості	(тобто	
частоти	виникнення)	РПХ	протягом	усього	періоду	спосте-
реження.	L-аскорбат	також	 істотно	пригнічував	генерацію	
РПХ.	Тривалість	цих	феноменів	 зменшувалася	помірно,	 а	
їх	кількість	скорочувалася	дуже	сильно.	У	групі	РМА	кіль-
кість	РПХ	протягом	першого	20-хвилинного	інтервалу	спо-
стереження	істотно	зростала	(на	50	%	,	P <	0.05),	але	цього	
не	спостерігалося	в	межах	наступних	 інтервалів.	Наші	ре-
зультати	підтверджують,	що	блокування	або	активація	каль-
цієвих	каналів	L-	та	T-типів	у	фокальній	кортикальній	зоні	
S1po	 здатні	 істотно	контролювати	 генерацію	РПХ	під	час	
прояву	абсансних	судом.	Обговорюються	можливі	механіз-
ми	дії	тестованих	агентів.
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